



From Kannan Natarajan

Senior Vice President, Biometrics and Data Management

Organization Announcement

Date: September 19, 2013

Dear BDM Colleagues:

Please find below organization announcements with BDM.

Insa Gathmann has been appointed as ad-interim Global Head of CDRR effective immediately. The ad-interim appointment will continue until Michael Murawsky's return to office. During this ad-interim tenure, Insa will lead CDRR with the Unit Heads – Andy Chopra, Priscilla Gathoni, Jahangir Kabir, Jia Lu, Mark Fairbrother, Michael Ball, Anne Mounier, Yvane Boudraa, Mahesh Iyer, and Junsuke Taniguchi and she will represent CDRR as a core member of the BDM Leadership team. In addition to her a.i. appointment, she will continue to lead her Unit within Full Development Biostatistics and report to Michael Branson, Global Head of Full Development Biostatistics.

Many of you are aware that Insa is extensively engaged and plays a key role in a broad series of business initiatives and in order to ensure that Insa has the time to lead, a.i., the BDM-CDRR organization and retain her Unit Head role, a transition plan is being carefully developed to ensure continuity for the business initiatives.

I would like to thank Insa for agreeing to support the broader BDM-CDRR organization through this a.i. appointment and look forward to collaborating with her at the BDM leadership team.

Samar Noor will lead the newly created group "Clinical Analytical Function" within BDM. Eric Kammer and the Data Review Team in US and India, currently reporting to Andy Chopra, will report now to Samar as part of this new group, effective immediately. The Clinical Analytical Function with the Data Review Team and 4 additional open positions in India is being created to enhance Data Visualization for the Clinical Trial teams using tools such as J-Review, Spotfire and TAPAS.

Samar will continue to lead the BDM Operations and Process Improvement group.

Armin Graber, Global Head of Clinical Biomarker Sciences and CDx – Bioinformatics and Biostatistics, has decided to leave BDM organization and join Genoptix (Novartis) to lead the Research & Product Development Group under Mike Nuerenberg, effective October 21st. We have begun a search internally and externally to fill his role. Douglas Robinson will be appointed as ad-interim head for CDx and CBSC Biostatistics group and will be a core member of the BDM Leadership Team.

I would like to thank Armin for his significant contributions during his tenure in BDM. Please join me in wishing him the very best for his future.


Michael Branson has been appointed as ad-interim Site Head and Deputy Global Head of BDM in Basel, effective immediately. The ad-interim appointment will continue until Michael Murawsky's return to office.

Beat Neuenschwander has been appointed as the Head of Statistical Methodology within BDM. Beat will continue to report to me and will be based in Basel, CH. Reporting to Beat in this new role will be Satrajit Roychoudhury.

Please join me in wishing all the new appointees the very best in their new roles.

Best Regards,

Kannan Natarajan
Global Head of Oncology Biometrics and Data Management



Blue lines = functional and operational reporting
Red lines = operational reporting

